Satellos Bioscience (MSLE) Short term Debt (2024 - 2025)
Satellos Bioscience's (MSLE) quarterly Short term Debt came in at $2.3 million in Q4 2025, up 48.75% year-on-year from $1.5 million in Q4 2024, and up 48.75% on a QoQ basis from $1.5 million in Q4 2024.
Satellos Bioscience (MSLE) Short term Debt (2024 - 2025) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Short term Debt data on file, last reported at $2.3 million in Q4 2025.
- On a quarterly basis, Short term Debt rose 48.75% year-over-year to $2.3 million in Q4 2025; TTM through Dec 2025 was $2.3 million, a 48.75% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 48.75% from the prior year.
- Short term Debt for Q4 2025 stood at $2.3 million, up from $1.5 million in the prior quarter.
- Over the last five years, Short term Debt for MSLE reached as high as $2.3 million in Q4 2025 and fell as low as $1.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Satellos Bioscience | 182.60 Mn | 182.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 1.52 Mn |